MX2017007054A - Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. - Google Patents

Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.

Info

Publication number
MX2017007054A
MX2017007054A MX2017007054A MX2017007054A MX2017007054A MX 2017007054 A MX2017007054 A MX 2017007054A MX 2017007054 A MX2017007054 A MX 2017007054A MX 2017007054 A MX2017007054 A MX 2017007054A MX 2017007054 A MX2017007054 A MX 2017007054A
Authority
MX
Mexico
Prior art keywords
urinary tract
lower urinary
solabegron
methods
tract symptoms
Prior art date
Application number
MX2017007054A
Other languages
English (en)
Inventor
Ohlstein Eliot
E Stevens Raymond
Jeffrey Wilkins H
Original Assignee
Velicept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velicept Therapeutics Inc filed Critical Velicept Therapeutics Inc
Publication of MX2017007054A publication Critical patent/MX2017007054A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta solicitud se refiere a composiciones farmacéuticas que comprenden solabegron que son útiles para el tratamiento de síntomas del tracto urinario inferior tales como, por ejemplo, trastornos de la próstata y vejiga hiperactiva. Adicionalmente, la solicitud se refiere a métodos para tratar síntomas del tracto urinario inferior utilizando las composiciones farmacéuticas que comprenden solabegron. En algunas modalidades, las composiciones farmacéuticas que comprenden solabegron comprenden un sistema de administración de fármaco de liberación dual.
MX2017007054A 2014-12-03 2015-12-03 Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. MX2017007054A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087021P 2014-12-03 2014-12-03
PCT/US2015/063795 WO2016090168A1 (en) 2014-12-03 2015-12-03 Compositions and methods of using modified release solabegron for lower urinary tract symptoms

Publications (1)

Publication Number Publication Date
MX2017007054A true MX2017007054A (es) 2018-05-02

Family

ID=56092482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007054A MX2017007054A (es) 2014-12-03 2015-12-03 Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.

Country Status (12)

Country Link
US (3) US9956194B2 (es)
EP (1) EP3226849A4 (es)
JP (1) JP2017537165A (es)
KR (1) KR20170086659A (es)
CN (1) CN107205964A (es)
AU (1) AU2015358378A1 (es)
CA (1) CA2969405A1 (es)
EA (1) EA201791225A1 (es)
HK (1) HK1245117A1 (es)
IL (1) IL252628A0 (es)
MX (1) MX2017007054A (es)
WO (1) WO2016090168A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
EP3463307A4 (en) * 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS
CN109803672A (zh) 2016-09-13 2019-05-24 阿勒根公司 稳定的非蛋白质梭菌毒素组合物
US20240197660A1 (en) * 2021-03-31 2024-06-20 B3Ar Therapeutics, Inc. Compositions of micronized solabegron and methods of use

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124473C (es) 1960-07-26
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
GB8519154D0 (en) 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
JPH0236571B2 (ja) * 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
DE3934436A1 (de) 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
ATE239694T1 (de) 1995-10-26 2003-05-15 Mitsubishi Pharma Corp Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
CA2653839A1 (en) 1998-11-02 2000-05-11 John G. Devane Multiparticulate modified release composition
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
AU2710301A (en) 2000-01-28 2001-08-07 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
US7034053B2 (en) 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
AU2002252364B2 (en) * 2001-03-13 2005-08-25 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
WO2003024483A1 (fr) 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1424079A1 (en) 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
AU2004285289A1 (en) 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
EP1694354B1 (en) 2003-11-27 2009-07-01 DeveloGen Aktiengesellschaft Method for preventing and treating diabetes using neurturin
ES2390879T3 (es) 2003-12-31 2012-11-19 Actavis Group Ptc Ehf. Formulaciones de atomoxetina
EP1550447A1 (en) 2004-01-02 2005-07-06 Schering Aktiengesellschaft Menstrual cycle control and improvement of conception rates in females
WO2005077364A1 (ja) 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
JP2008516909A (ja) 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用
BRPI0609962B1 (pt) 2005-04-19 2022-01-18 Novartis Ag Composição farmacêutica oral
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US20100113469A1 (en) 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
GB0714790D0 (en) 2007-07-30 2007-09-12 Jagotec Ag Improvements in or relating to organic compounds
US20100240697A1 (en) 2007-11-02 2010-09-23 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
CA2719907A1 (en) 2008-04-04 2009-10-08 Merck Sharp & Dohme Corp. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
WO2010118291A2 (en) 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EP2427194B1 (en) 2009-05-08 2014-10-08 Merck Sharp & Dohme Corp. Pyrrolidine-derived beta 3 adrenergic receptor agonists
US8586760B2 (en) 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
WO2011025690A1 (en) 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
MX2012002366A (es) 2009-08-27 2012-03-29 Merck Sharp & Dohme Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
MX2012004134A (es) 2009-10-07 2012-05-08 Merck Sharp & Dohme Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico.
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2016004056A1 (en) 2014-07-03 2016-01-07 Velicept Therapeutics, Inc. Pharmaceutical combinations
CN103269692B (zh) * 2010-08-03 2018-02-23 韦利塞普特治疗有限公司 用于治疗膀胱过度活动症的β‑3肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂的药物组合
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
AU2013216864A1 (en) 2012-02-09 2014-09-11 Altherx, Inc. Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
EA201590449A1 (ru) 2012-08-31 2015-06-30 Астеллас Фарма Инк. Перорально вводимая лекарственная композиция
US20150306170A1 (en) 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
WO2014134005A2 (en) 2013-02-26 2014-09-04 Xenoport, Inc. Method of making 1-(acyloxy)-alkyl carbamate compounds
WO2014171542A1 (ja) * 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
CN105579057A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
EP3102190A4 (en) 2014-02-07 2017-09-06 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
JP2017078023A (ja) 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
WO2017186598A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3463312A4 (en) 2016-06-03 2020-02-05 Velicept Therapeutics, Inc. DOSING SCHEMES FOR BETA-3-ADRENOCEPTORAGONISTS AND ANTIMUS CARINICAS FOR THE TREATMENT AND PREVENTION OF SYMPTOMS OF THE LOWER URINARY PATHWAYS AND OVERACTIVE BLADDER
EP3463307A4 (en) 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS

Also Published As

Publication number Publication date
CN107205964A (zh) 2017-09-26
KR20170086659A (ko) 2017-07-26
HK1245117A1 (zh) 2018-08-24
US20190083434A1 (en) 2019-03-21
AU2015358378A1 (en) 2017-06-29
EA201791225A1 (ru) 2017-12-29
US20160158176A1 (en) 2016-06-09
JP2017537165A (ja) 2017-12-14
US20190083433A1 (en) 2019-03-21
EP3226849A4 (en) 2018-05-09
EP3226849A1 (en) 2017-10-11
WO2016090168A1 (en) 2016-06-09
US9956194B2 (en) 2018-05-01
US10751311B2 (en) 2020-08-25
IL252628A0 (en) 2017-07-31
CA2969405A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
MX2017007054A (es) Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
IN2014MU00303A (es)
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
WO2017070689A3 (en) Solabegron zwitterion and uses thereof
HK1197235A1 (zh) 二氫吡唑、其藥物組合物及其治療生育障礙的用途
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EA201691964A1 (ru) Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии
WO2015200768A3 (en) Pharmacologic treatments of menière's disease